IS Pharma launches Variquel in the UK

PHARMACEUTICAL firm IS Pharma is launching its Variquel drug in UK and Ireland.

The Chester-based company said the earlier than expected launch follows recent approval by the UK regulatory authority (MHRA), and it now expects to roll out the drug across Europe.

Variquel, which is used in the treatment of bleeding oesophageal varices , is a key global brand for IS Pharma  and has a global market estimated at around £70m.

In America , Lucassin- Variquel – has recently been granted priority review as well as fast track designation by the US Food and Drug Administration for the treatment of hepatorenal syndrome – renal failure as a result of chronic liver disease.

IS Pharma chief executive  Tim Wright said the commercial launch of Variquel after  only recently receiving the marketing authorisation from the UK regulatory authority MHRA)highlights the ability of IS Pharma to quickly bring its key brands to market.

He added: “We now have distributors in place across Europe ready to replicate the UK launch the moment marketing authorisations are received. The continued regulatory progress of the brand in the US is also very encouraging.”